Nuvelo

Nuvelo, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular

Nuvelo, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. The Company’s development pipeline includes alfimeprase, a direct-acting fibrinolytic in Phase II development for the treatment of thrombotic-related disorders, including acute ischemic stroke and catheter occlusion (CO); NU172, a direct thrombin inhibitor in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures, and preclinical candidate NU206 for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. (Source: 10-K)